TAURX
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), today announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration. Blood concentration of NfL showed a statistically significant 93% reduction in change over 12 months in participants receiving HMTM at a dose of 16 mg/day relative to the control group, which correlated significantly with a tau biomarker (p-tau 181) in blood.
Neurofilaments and tau proteins are essential for neuronal structure and function in the brain. In AD, tau protein aggregates to form toxic fibrils, which damage neurons. The extent of this damage can be measured by the amount of leakage of neurofilament protein into the bloodstream. NfL concentration in blood is known to correlate with tau pathology, disease severity, and therefore cognitive decline and brain atrophy in AD. HMTM, a tau aggregation inhibitor, was designed to reduce tau pathology in AD. Changes in NfL concentration by HMTM indicate a direct impact on disease pathology.
“NfL is a well-studied biomarker with wide applicability to different neurological disorders, including AD,” said Henrik Zetterberg, Professor of Neurochemistry, UCL Queen Square Institute of Neurology. “Clinical practice has been waiting decades to uncover meaningful advancements to address unmet needs of people with AD. These new results further support the importance of NfL as an AD biomarker both for diagnosis and measurement of treatment effect.”
“The NfL results demonstrate that a drug targeting tau pathology reduces the neurodegeneration that underlies clinical decline in AD,” said Claude Wischik, Executive Chairman, TauRx. “They bring us a step closer to offering an effective new treatment option for people with AD. Because it is taken as a tablet and has a strong safety profile, HMTM would be readily accessible to people needing a disease modifying treatment.”
TauRx will submit the HMTM results from LUCIDITY and earlier trials for regulatory approval in the US, UK and other territories.
For additional information, visit: https://taurx.com/ or https://aaic.alz.org/program/scientific-sessions.asp.
THE LUCIDITY TRIAL
LUCIDITY comprised a 12-month double-blind controlled Phase 3 clinical trial followed by a 12-month period in which all participants received HMTM at 16 mg/day. The trial investigated change in various clinical and biomarker outcomes comparing HMTM 16 mg/day with methylthioninium chloride (MTC) given 4 mg twice weekly as a control over the first 12 months. NfL was the principal blood biomarker endpoint in this study. The LUCIDITY trial is now complete and TauRx is preparing publications to report both the NfL data and the full 24-month data.
TAU PATHOLOGY IN AD
Age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in AD. Tau aggregation begins many years before symptoms of dementia appear. Tau aggregation pathology correlates with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with AD, establishing it as an important target for treatment. HMTM works by inhibiting pathological aggregation of tau protein.
ABOUT TAURX PHARMACEUTICALS LTD
TauRx was founded in 2002 in Singapore, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer’s and other neurodegenerative diseases due to protein aggregation pathology.
Alzheimer’s disease is a leading cause of disability and death throughout the world and is one of the most important public health issues that need to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to make HMTM available to patients and pursue clinical development in other related neurodegenerative diseases. https://www.taurx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230715707201/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting samarbejder med MJB Technology Solutions om at fremme digitale transformationsmuligheder7.9.2025 08:24:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin platform for digital transformation gennem et samarbejde med det canadiske firma MJB Technology Solutions, der er specialiseret i ServiceNow, kunstig intelligens, analyse og IT-transformation. MJB Technology Solutions blev stiftet i 2002 og udvikler skræddersyet software, digitale platforme og operationelle systemer til kunder inden for sektorer som banker, telekommunikation og produktion. Virksomhedens kernekompetencer omfatter komplekse ServiceNow-tjenester samt AI-baserede løsninger, business intelligence og analyse samt digital IT-strategi – og de leverer konsekvent målbare resultater og langsigtet værdi. "Gennem to årtier har vi leveret specialudviklede løsninger, der hjælper vores kunder med at tackle forretningskritiske udfordringer," siger Mark Bains, administrerende direktør hos MJB Technology Solutions. "Vores samarbejde med Andersen Consulting markerer et nyt kapitel i, hvordan vi skalerer innovation globalt, samtidig med at vi forbliver tro m
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 02:45:00 CEST | Press release
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 − VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in Adults and Children with VWD1 − VWD, the Most Common Bleeding Disorder, Impacts More Than 3 Million People in the U.S.2 Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approve
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20255.9.2025 23:34:00 CEST | Press release
From well-being to energy efficiency, Bespoke AI, Vision AI, and Galaxy AI transform the way we live and connect. At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology support
Andersen Consulting styrker end-to-end-teknologikompetencer via samarbejde med FirstQA Systems5.9.2025 19:44:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation og kunstig intelligens via en samarbejdsaftale med FirstQA Systems, der er en førende teknologileverandør, som er kendt for sin ekspertise inden for AI til virksomheder, digital transformation og cybersikkerhed. FirstQA Systems K.K. med hovedsæde i Japan siden 2011 er en konsulentdrevet teknologivirksomhed, der betjener Fortune 500-virksomheder og multinationale koncerner i Asien, Europa og Nordamerika. Virksomheden specialiserer sig i kunstig intelligens, digital transformation (med fokus på platformene ServiceNow, SAP og Salesforce) samt it- og OT-cybersikkerhed. Gennem sit datterselskab, Himitsu Lab Limited, leverer FirstQA Systems banebrydende Agentic AI-løsninger drevet af HIMITSU8™ Unified Development Framework (UDF)™. Virksomhedens brancheekspertise dækker bl.a. produktion, medicinalindustrien samt løsninger til bank- og finansverdenen. "Vores samarbejde med Andersen Consulting markerer et spændende sk
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 17:15:00 CEST | Press release
Recognition reflects NetApp’s Ability to Execute and Completeness of Vision NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.”
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom